A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Completed · Phase 3 · NCT06097273
Conditions: SARS-CoV-2, Influenza
At a glance
- Research payments reported, 2025
- $78,673
- U.S. investigators named
- 15
- Sites paid
- 11
- Planned or actual enrollment
- 8,061
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1083 (biological), Placebo (biological), Influenza Vaccine (biological), COVID-19 Vaccine (biological)
- Dates
- Started 2023-10-19; completion 2024-05-28
- Results posted
- Yes
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
From ClinicalTrials.gov, last updated 2025-07-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $78,673 in research payments for this study in 2025 (28 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Faisal Amin, M.D. Family Medicine · Miramar, FL
- Jose F. Cardona, M.D. General Practice · Miami, FL
- Mark J. Rosenthal, D.O. Family Medicine · Homestead, FL
- Danny H. Sugimoto, MD Internal Medicine · Chicago, IL
- Nathan H. Fischman, M.D. Specialist · Metairie, LA
- John W. Benson, MD Family Medicine · Mankato, MN
- David G. True, D.O. Rheumatology · Nixa, MO
- Alexander Ryan, D.O. Internal Medicine · Lincoln, NE
- Charles Lunn JR. Family Medicine · Oklahoma City, OK
- Donald Eagerton, M.D. Endocrinology & Diabetes · Myrtle Beach, SC
- Douglas S. Denham, D.O. Family Medicine · San Antonio, TX
- Lisa R. Holloway, D.O. Family Medicine · Houston, TX
- Vicki E. Miller, M.D. Family Medicine · Pasadena, TX
- Yvette M. Poindexter, MD Family Medicine · Pearland, TX
- Efrain E. Soto, MD Family Medicine · Friendswood, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Pharmaseek LLC $28,701
- Clinical Site PArtners $9,800
- Clinical Trials of Texas Inc. $8,800
- Trial Management Associates LLC $8,225
- Clinvest Headlands LLC $7,800
- Dynamed Clinical Research LP $5,750
- Javara Inc $3,620
- Be Well Clinical Studies LLC $3,500
- Indago Research and Health Center Inc $1,013
- Delricht LLC $965
- Lynn Health Science Institute $500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.